MDxHealth SA ADR (MDXH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, MDxHealth SA ADR (MDXH) has a cash flow conversion efficiency ratio of -0.031x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($378.00K) by net assets ($-12.09 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See MDxHealth SA ADR net asset quality index to measure how much of total assets are equity-financed.
MDxHealth SA ADR - Cash Flow Conversion Efficiency Trend (2004–2025)
This chart illustrates how MDxHealth SA ADR's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check MDXH cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
MDxHealth SA ADR Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of MDxHealth SA ADR ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Paramount Gold Nevada Corp
NYSE MKT:PZG
|
0.070x |
|
Acres Commercial Realty Corp
NYSE:ACR
|
-0.022x |
|
Mitrajaya Holdings Bhd
KLSE:9571
|
0.097x |
|
Stellar Resources Ltd
AU:SRZ
|
-0.353x |
|
Reward Wool Industry Corp
TW:1423
|
0.004x |
|
Business Alignment Public Company Limited
BK:BIZ
|
-0.101x |
|
ARRAIL GROUP LTD.
F:I1D
|
N/A |
|
Poh Kong Holdings Bhd
KLSE:5080
|
-0.004x |
Annual Cash Flow Conversion Efficiency for MDxHealth SA ADR (2004–2025)
The table below shows the annual cash flow conversion efficiency of MDxHealth SA ADR from 2004 to 2025. For the full company profile with market capitalisation and key ratios, see MDxHealth SA ADR market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-12.09 Million | $-10.42 Million | 0.861x | +168.99% |
| 2024-12-31 | $14.84 Million | $-18.53 Million | -1.249x | +58.14% |
| 2023-12-31 | $7.21 Million | $-21.50 Million | -2.982x | +18.57% |
| 2022-12-31 | $9.31 Million | $-34.12 Million | -3.663x | -661.83% |
| 2021-12-31 | $46.90 Million | $-22.55 Million | -0.481x | +86.11% |
| 2020-12-31 | $5.85 Million | $-20.24 Million | -3.461x | -206.28% |
| 2019-12-31 | $19.72 Million | $-22.29 Million | -1.130x | -106.34% |
| 2018-12-31 | $52.12 Million | $-28.54 Million | -0.548x | -127.37% |
| 2017-12-31 | $43.55 Million | $-10.49 Million | -0.241x | +23.40% |
| 2016-12-31 | $52.74 Million | $-16.59 Million | -0.314x | +3.30% |
| 2015-12-31 | $44.26 Million | $-14.39 Million | -0.325x | +58.24% |
| 2014-12-31 | $23.78 Million | $-18.51 Million | -0.779x | -35.45% |
| 2013-12-31 | $24.54 Million | $-14.11 Million | -0.575x | +18.11% |
| 2012-12-31 | $16.02 Million | $-11.25 Million | -0.702x | -21.14% |
| 2011-12-31 | $14.67 Million | $-8.50 Million | -0.580x | +23.56% |
| 2010-12-31 | $14.26 Million | $-10.81 Million | -0.758x | -11.36% |
| 2009-12-31 | $26.94 Million | $-18.34 Million | -0.681x | -138.61% |
| 2008-12-31 | $45.44 Million | $-12.96 Million | -0.285x | +13.86% |
| 2007-12-31 | $49.75 Million | $-16.48 Million | -0.331x | -104.43% |
| 2006-12-31 | $42.21 Million | $-6.84 Million | -0.162x | +60.09% |
| 2005-12-31 | $11.95 Million | $-4.85 Million | -0.406x | +53.41% |
| 2004-12-31 | $7.04 Million | $-6.14 Million | -0.871x | -- |
About MDxHealth SA ADR
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company's testing solutions include Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the… Read more